ZA200404845B - 2-Indaylamino derivatives for the therapy of chronic pain - Google Patents
2-Indaylamino derivatives for the therapy of chronic pain Download PDFInfo
- Publication number
- ZA200404845B ZA200404845B ZA200404845A ZA200404845A ZA200404845B ZA 200404845 B ZA200404845 B ZA 200404845B ZA 200404845 A ZA200404845 A ZA 200404845A ZA 200404845 A ZA200404845 A ZA 200404845A ZA 200404845 B ZA200404845 B ZA 200404845B
- Authority
- ZA
- South Africa
- Prior art keywords
- alkyl
- pain
- hydrogen
- chronic
- chronic pain
- Prior art date
Links
- 208000002193 Pain Diseases 0.000 title claims description 36
- 208000000094 Chronic Pain Diseases 0.000 title claims description 17
- 238000002560 therapeutic procedure Methods 0.000 title description 3
- 125000000217 alkyl group Chemical group 0.000 claims description 22
- 150000001875 compounds Chemical class 0.000 claims description 17
- 229910052739 hydrogen Inorganic materials 0.000 claims description 12
- 238000011282 treatment Methods 0.000 claims description 12
- 239000001257 hydrogen Substances 0.000 claims description 10
- 208000032131 Diabetic Neuropathies Diseases 0.000 claims description 8
- 210000005036 nerve Anatomy 0.000 claims description 8
- -1 propanoyloxy Chemical group 0.000 claims description 8
- 230000001684 chronic effect Effects 0.000 claims description 7
- 230000006378 damage Effects 0.000 claims description 7
- 208000004296 neuralgia Diseases 0.000 claims description 7
- 208000021722 neuropathic pain Diseases 0.000 claims description 7
- 206010065390 Inflammatory pain Diseases 0.000 claims description 6
- 206010036376 Postherpetic Neuralgia Diseases 0.000 claims description 6
- 230000001154 acute effect Effects 0.000 claims description 6
- 201000010099 disease Diseases 0.000 claims description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 6
- 206010028980 Neoplasm Diseases 0.000 claims description 5
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims description 5
- 206010044652 trigeminal neuralgia Diseases 0.000 claims description 5
- 241000725303 Human immunodeficiency virus Species 0.000 claims description 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 4
- 208000005298 acute pain Diseases 0.000 claims description 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 4
- 208000008035 Back Pain Diseases 0.000 claims description 3
- 208000008930 Low Back Pain Diseases 0.000 claims description 3
- 108090001041 N-Methyl-D-Aspartate Receptors Proteins 0.000 claims description 3
- 206010003246 arthritis Diseases 0.000 claims description 3
- 201000011510 cancer Diseases 0.000 claims description 3
- 150000002431 hydrogen Chemical class 0.000 claims description 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 3
- 239000008194 pharmaceutical composition Substances 0.000 claims description 3
- 150000003839 salts Chemical class 0.000 claims description 3
- 208000001640 Fibromyalgia Diseases 0.000 claims description 2
- 108090000862 Ion Channels Proteins 0.000 claims description 2
- 102000004310 Ion Channels Human genes 0.000 claims description 2
- 208000019695 Migraine disease Diseases 0.000 claims description 2
- 102000004868 N-Methyl-D-Aspartate Receptors Human genes 0.000 claims description 2
- 230000002401 inhibitory effect Effects 0.000 claims description 2
- 206010019233 Headaches Diseases 0.000 claims 1
- 125000003668 acetyloxy group Chemical group [H]C([H])([H])C(=O)O[*] 0.000 claims 1
- 125000001231 benzoyloxy group Chemical group C(C1=CC=CC=C1)(=O)O* 0.000 claims 1
- 231100000869 headache Toxicity 0.000 claims 1
- 206010027599 migraine Diseases 0.000 claims 1
- MNLULKBKWKTZPE-UHFFFAOYSA-N indantadol Chemical compound C1=CC=C2CC(NCC(=O)N)CC2=C1 MNLULKBKWKTZPE-UHFFFAOYSA-N 0.000 description 15
- 208000004454 Hyperalgesia Diseases 0.000 description 12
- 230000000694 effects Effects 0.000 description 11
- 241001465754 Metazoa Species 0.000 description 10
- 241000700159 Rattus Species 0.000 description 7
- 230000000202 analgesic effect Effects 0.000 description 6
- 206010053552 allodynia Diseases 0.000 description 5
- 210000000548 hind-foot Anatomy 0.000 description 5
- 206010010904 Convulsion Diseases 0.000 description 4
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 4
- 210000002683 foot Anatomy 0.000 description 4
- 208000014674 injury Diseases 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- HOKKHZGPKSLGJE-GSVOUGTGSA-N N-Methyl-D-aspartic acid Chemical compound CN[C@@H](C(O)=O)CC(O)=O HOKKHZGPKSLGJE-GSVOUGTGSA-N 0.000 description 3
- 208000027418 Wounds and injury Diseases 0.000 description 3
- 239000000730 antalgic agent Substances 0.000 description 3
- 210000003169 central nervous system Anatomy 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 206010058019 Cancer Pain Diseases 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 208000001294 Nociceptive Pain Diseases 0.000 description 2
- 229940113118 carrageenan Drugs 0.000 description 2
- 235000010418 carrageenan Nutrition 0.000 description 2
- 229920001525 carrageenan Polymers 0.000 description 2
- 239000000679 carrageenan Substances 0.000 description 2
- 230000009977 dual effect Effects 0.000 description 2
- 210000003141 lower extremity Anatomy 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 2
- 230000003040 nociceptive effect Effects 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 125000003884 phenylalkyl group Chemical group 0.000 description 2
- 238000011552 rat model Methods 0.000 description 2
- 230000011514 reflex Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 210000003497 sciatic nerve Anatomy 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 230000001256 tonic effect Effects 0.000 description 2
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 2
- HVYRKWVGZVDZMP-UHFFFAOYSA-N 2-(2,3-dihydro-1h-inden-2-ylamino)-3-hydroxypropanamide;hydrochloride Chemical compound Cl.C1=CC=C2CC(NC(CO)C(=O)N)CC2=C1 HVYRKWVGZVDZMP-UHFFFAOYSA-N 0.000 description 1
- KOWJSIYQEMNINI-UHFFFAOYSA-N 2-(2,3-dihydro-1h-inden-2-ylamino)propanamide;hydrochloride Chemical compound Cl.C1=CC=C2CC(NC(C)C(N)=O)CC2=C1 KOWJSIYQEMNINI-UHFFFAOYSA-N 0.000 description 1
- 208000030090 Acute Disease Diseases 0.000 description 1
- 206010003591 Ataxia Diseases 0.000 description 1
- 208000025940 Back injury Diseases 0.000 description 1
- IYGYMKDQCDOMRE-QRWMCTBCSA-N Bicculine Chemical compound O([C@H]1C2C3=CC=4OCOC=4C=C3CCN2C)C(=O)C2=C1C=CC1=C2OCO1 IYGYMKDQCDOMRE-QRWMCTBCSA-N 0.000 description 1
- 206010053398 Clonic convulsion Diseases 0.000 description 1
- 206010012289 Dementia Diseases 0.000 description 1
- 206010019196 Head injury Diseases 0.000 description 1
- 208000023105 Huntington disease Diseases 0.000 description 1
- 208000035154 Hyperesthesia Diseases 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 208000029462 Immunodeficiency disease Diseases 0.000 description 1
- 206010027603 Migraine headaches Diseases 0.000 description 1
- 208000028389 Nerve injury Diseases 0.000 description 1
- 102000004316 Oxidoreductases Human genes 0.000 description 1
- 108090000854 Oxidoreductases Proteins 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- LHNKBXRFNPMIBR-UHFFFAOYSA-N Picrotoxin Natural products CC(C)(O)C1(O)C2OC(=O)C1C3(O)C4OC4C5C(=O)OC2C35C LHNKBXRFNPMIBR-UHFFFAOYSA-N 0.000 description 1
- 206010039897 Sedation Diseases 0.000 description 1
- 206010043994 Tonic convulsion Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 230000001773 anti-convulsant effect Effects 0.000 description 1
- 230000003556 anti-epileptic effect Effects 0.000 description 1
- 230000003070 anti-hyperalgesia Effects 0.000 description 1
- 239000001961 anticonvulsive agent Substances 0.000 description 1
- 239000000935 antidepressant agent Substances 0.000 description 1
- 229960003965 antiepileptics Drugs 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- AACMFFIUYXGCOC-UHFFFAOYSA-N bicuculline Natural products CN1CCc2cc3OCOc3cc2C1C4OCc5c6OCOc6ccc45 AACMFFIUYXGCOC-UHFFFAOYSA-N 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 230000001010 compromised effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- IYGYMKDQCDOMRE-UHFFFAOYSA-N d-Bicucullin Natural products CN1CCC2=CC=3OCOC=3C=C2C1C1OC(=O)C2=C1C=CC1=C2OCO1 IYGYMKDQCDOMRE-UHFFFAOYSA-N 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000007813 immunodeficiency Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 231100000225 lethality Toxicity 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229960005181 morphine Drugs 0.000 description 1
- 230000004118 muscle contraction Effects 0.000 description 1
- 239000003703 n methyl dextro aspartic acid receptor blocking agent Substances 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000003136 n-heptyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 230000008764 nerve damage Effects 0.000 description 1
- 210000004126 nerve fiber Anatomy 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 230000000626 neurodegenerative effect Effects 0.000 description 1
- 230000002981 neuropathic effect Effects 0.000 description 1
- 201000001119 neuropathy Diseases 0.000 description 1
- 230000007823 neuropathy Effects 0.000 description 1
- 210000000929 nociceptor Anatomy 0.000 description 1
- 108091008700 nociceptors Proteins 0.000 description 1
- 230000000414 obstructive effect Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 210000001428 peripheral nervous system Anatomy 0.000 description 1
- 208000033808 peripheral neuropathy Diseases 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 238000011458 pharmacological treatment Methods 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- VJKUPQSHOVKBCO-AHMKVGDJSA-N picrotoxin Chemical compound O=C([C@@]12O[C@@H]1C[C@]1(O)[C@@]32C)O[C@@H]3[C@H]2[C@@H](C(=C)C)[C@@H]1C(=O)O2.O=C([C@@]12O[C@@H]1C[C@]1(O)[C@@]32C)O[C@@H]3[C@H]2[C@@H](C(C)(O)C)[C@@H]1C(=O)O2 VJKUPQSHOVKBCO-AHMKVGDJSA-N 0.000 description 1
- 229940124606 potential therapeutic agent Drugs 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000026416 response to pain Effects 0.000 description 1
- 230000036280 sedation Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 230000003238 somatosensory effect Effects 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000002889 sympathetic effect Effects 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000036962 time dependent Effects 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 239000011800 void material Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP01130638A EP1321139B1 (en) | 2001-12-21 | 2001-12-21 | 2-Indanylamino deratives for the therapy of chronic, acute or inflammatory pain |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA200404845B true ZA200404845B (en) | 2006-07-26 |
Family
ID=8179649
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA200404845A ZA200404845B (en) | 2001-12-21 | 2004-06-18 | 2-Indaylamino derivatives for the therapy of chronic pain |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US20050222266A1 (da) |
| EP (2) | EP1321139B1 (da) |
| JP (1) | JP4427329B2 (da) |
| AT (1) | ATE336990T1 (da) |
| BR (1) | BR0207371A (da) |
| CA (1) | CA2470990C (da) |
| DE (1) | DE60122541T2 (da) |
| DK (1) | DK1321139T3 (da) |
| ES (1) | ES2270947T3 (da) |
| HU (1) | HUP0402664A3 (da) |
| MX (1) | MXPA04005884A (da) |
| NO (1) | NO20033670L (da) |
| NZ (1) | NZ533537A (da) |
| PL (1) | PL207015B1 (da) |
| PT (1) | PT1321139E (da) |
| SI (1) | SI1321139T1 (da) |
| WO (1) | WO2003053429A2 (da) |
| ZA (1) | ZA200404845B (da) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ565416A (en) * | 2005-07-28 | 2011-03-31 | Chiesi Farma Spa | Therapeutic combination comprising a NMDA receptors blocker and a narcotic analgesic substance |
| KR102014203B1 (ko) | 2011-02-18 | 2019-08-26 | 아사나 바이오사이언시스 엘엘씨 | 아미노인단 화합물 및 통증 치료에서 그것의 용도 |
| US9044482B2 (en) | 2012-08-15 | 2015-06-02 | Asana Biosciences, Llc | Use of aminoindane compounds in treating overactive bladder and interstitial cystitis |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2115792C (en) * | 1993-03-05 | 2005-11-01 | David J. Mayer | Method for the treatment of pain |
| IT1283489B1 (it) * | 1996-07-23 | 1998-04-21 | Chiesi Farma Spa | Ammidi di alfa-amminoacidi,loro preparazione e loro impiego terapeutico |
| AU7472898A (en) * | 1997-05-07 | 1998-11-27 | Algos Pharmaceutical Corporation | Composition and method combining an antidepressant with an nmda receptor antagonist, for treating neuropathic pain |
| NZ515143A (en) * | 1999-06-10 | 2004-05-28 | Bridge Pharma Inc | Aminoindane piperidine compounds as dermal anesthetic agents |
-
2001
- 2001-12-21 DK DK01130638T patent/DK1321139T3/da active
- 2001-12-21 ES ES01130638T patent/ES2270947T3/es not_active Expired - Lifetime
- 2001-12-21 DE DE60122541T patent/DE60122541T2/de not_active Expired - Lifetime
- 2001-12-21 AT AT01130638T patent/ATE336990T1/de active
- 2001-12-21 PT PT01130638T patent/PT1321139E/pt unknown
- 2001-12-21 EP EP01130638A patent/EP1321139B1/en not_active Expired - Lifetime
- 2001-12-21 SI SI200130651T patent/SI1321139T1/sl unknown
-
2002
- 2002-12-06 WO PCT/EP2002/013839 patent/WO2003053429A2/en active IP Right Grant
- 2002-12-06 JP JP2003554186A patent/JP4427329B2/ja not_active Expired - Fee Related
- 2002-12-06 US US10/498,350 patent/US20050222266A1/en not_active Abandoned
- 2002-12-06 PL PL370763A patent/PL207015B1/pl not_active IP Right Cessation
- 2002-12-06 NZ NZ533537A patent/NZ533537A/en not_active IP Right Cessation
- 2002-12-06 CA CA2470990A patent/CA2470990C/en not_active Expired - Fee Related
- 2002-12-06 BR BR0207371-4A patent/BR0207371A/pt not_active IP Right Cessation
- 2002-12-06 MX MXPA04005884A patent/MXPA04005884A/es active IP Right Grant
- 2002-12-06 EP EP02790474A patent/EP1455771B1/en not_active Expired - Lifetime
- 2002-12-06 HU HU0402664A patent/HUP0402664A3/hu unknown
-
2003
- 2003-08-19 NO NO20033670A patent/NO20033670L/no not_active Application Discontinuation
-
2004
- 2004-06-18 ZA ZA200404845A patent/ZA200404845B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP4427329B2 (ja) | 2010-03-03 |
| WO2003053429A2 (en) | 2003-07-03 |
| EP1455771B1 (en) | 2006-11-08 |
| NO20033670D0 (no) | 2003-08-19 |
| MXPA04005884A (es) | 2004-11-01 |
| EP1321139A1 (en) | 2003-06-25 |
| EP1455771A2 (en) | 2004-09-15 |
| AU2002366727A1 (en) | 2003-07-09 |
| US20050222266A1 (en) | 2005-10-06 |
| PL207015B1 (pl) | 2010-10-29 |
| JP2005513101A (ja) | 2005-05-12 |
| ATE336990T1 (de) | 2006-09-15 |
| ES2270947T3 (es) | 2007-04-16 |
| NO20033670L (no) | 2003-10-21 |
| DE60122541T2 (de) | 2007-09-13 |
| SI1321139T1 (sl) | 2007-02-28 |
| EP1321139B1 (en) | 2006-08-23 |
| HUP0402664A2 (hu) | 2005-04-28 |
| HUP0402664A3 (en) | 2012-05-29 |
| WO2003053429A3 (en) | 2003-07-31 |
| DE60122541D1 (de) | 2006-10-05 |
| NZ533537A (en) | 2006-08-31 |
| BR0207371A (pt) | 2004-02-10 |
| CA2470990A1 (en) | 2003-07-03 |
| CA2470990C (en) | 2011-03-29 |
| PL370763A1 (en) | 2005-05-30 |
| PT1321139E (pt) | 2007-01-31 |
| DK1321139T3 (da) | 2007-01-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US7875652B2 (en) | Method and composition for treating pain or tinnitus aureum | |
| CN103025326B (zh) | 治疗不安腿综合征的方法 | |
| KR101783633B1 (ko) | 섬유근육통 증후군의 치료 방법 | |
| US10905672B2 (en) | Combination of baclofen, acamprosate and medium chain triglycerides for the treatment of neurological disorders | |
| SK283222B6 (sk) | Použitie 2-amino-4-(4-fluórbenzylamino)-1- etoxykarbonylaminobenzénu na výrobu liečiv na profylaxiu a liečenie následkov akútnej a chronickej mozgovej nedokrvenosti mozgu a neurodegeneratívnych chorôb | |
| WO2013063289A1 (en) | Pharmaceutical compositions for treating pain | |
| RU2336077C2 (ru) | Альфа-аминоамидные производные, применимые в качестве антимигренозных средств | |
| US20010031789A1 (en) | Use of valproic acid analog for the treatment and prevention of migraine and affective illness | |
| CZ20032298A3 (cs) | Léčivo pro léčbu bolesti | |
| JP5271473B2 (ja) | 神経障害性疼痛ならびに群発性頭痛および偏頭痛に関連する疼痛の予防もしくは治療における使用のためのカルバメート化合物 | |
| EP1321139B1 (en) | 2-Indanylamino deratives for the therapy of chronic, acute or inflammatory pain | |
| JP5341037B2 (ja) | 双極性障害を処置するための医薬を得るためのアゴメラチンの使用 | |
| AU2002366727B2 (en) | 2-indanylamino derivatives for the therapy of chronic pain | |
| CN115212194B (zh) | 纳多洛尔在制备治疗缺血/再灌注损伤药物及细胞保护药物中的应用 | |
| JP4362367B2 (ja) | 神経因性疼痛および群発および偏頭痛に伴う疼痛の防止または処置に使用するためのカルバメート化合物 | |
| JP4362368B2 (ja) | 神経因性疼痛および群発および偏頭痛に伴う疼痛の防止または処置に使用するためのカルバメート化合物 | |
| JP7065880B2 (ja) | アルツハイマー病のイダロピルジン系組合せ療法 | |
| US20150258073A1 (en) | INDICATION OF ANTHRA[2,1,c][1,2,5]THIADIAZOLE-6,11-DIONE COMPOUND IN ALLEVIATING PAIN | |
| KR101779135B1 (ko) | 덱사메타손과 이부프로펜을 유효성분으로 포함하는 신경병증성 통증 예방 및 치료용 약학적 조성물 | |
| ES2323981T3 (es) | Tiazolopirimidinas para uso en terapia. | |
| NZ549727A (en) | Use of a combination of agomelatine and a thymoregulatory agent for treating mood disorders | |
| KR20090002888A (ko) | 파킨슨씨 병을 포함한 뇌신경질환 치료효과 및 뇌보호효과를 갖는 치환된 벤젠 유도체 화합물을 포함하는약제학적 조성물 및 상기 화합물을 이용한 뇌질환 치료방법 |